- Acquisition includes ozureprubart, a potentially best-in-class anti-IgE antibody, in development for prophylactic protection against food allergens
- Ozureprubart offers potential to protect against food allergy reactions with less frequent dosing compared to existing standard-of-care therapy
- Food allergies are increasing with significant unmet need and serious health risks
- Acquisition adds to Respiratory, Immunology & Inflammation pipeline
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.